2021
Phytocannabinoids and schizophrenia: Focus on adolescence as a critical window of enhanced vulnerability and opportunity for treatment
ŠTARK, Tibor, S. DI MARTINO, F. DRAGO, C. T. WOTJAK, V. MICALE et. al.Základní údaje
Originální název
Phytocannabinoids and schizophrenia: Focus on adolescence as a critical window of enhanced vulnerability and opportunity for treatment
Autoři
ŠTARK, Tibor (703 Slovensko, domácí), S. DI MARTINO, F. DRAGO, C. T. WOTJAK a V. MICALE (garant)
Vydání
Pharmacological Research, London, ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD, 2021, 1043-6618
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30104 Pharmacology and pharmacy
Stát vydavatele
Německo
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 10.334
Kód RIV
RIV/00216224:14110/21:00124165
Organizační jednotka
Lékařská fakulta
UT WoS
000724713300004
Klíčová slova anglicky
THC; Cannabidiol; Adolescence; Schizophrenia; Animal model; Neurodevelopment
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 15. 2. 2022 13:37, Mgr. Tereza Miškechová
Anotace
V originále
The recent shift in socio-political debates and growing liberalization of Cannabis use across the globe has raised concern regarding its impact on vulnerable populations such as adolescents. Concurrent with declining perception of Cannabis harms, more adolescents are using it daily in several countries and consuming marijuana strains with high content of psychotropic delta (9)-tetrahydrocannabinol (THC). These dual, related trends seem to facilitate the development of compromised social and cognitive performance at adulthood, which are described in preclinical and human studies. Cannabis exerts its effects via altering signalling within the endocannabinoid system (ECS), which modulates the stress circuitry during the neurodevelopment. In this context early interventions appear to circumvent the emergence of adult neurodevelopmental deficits. Accordingly, Cannabis sativa second-most abundant compound, cannabidiol (CBD), emerges as a potential therapeutic agent to treat neuropsychiatric disorders. We first focus on human and preclinical studies on the long-term effects induced by adolescent THC exposure as a "critical window" of enhanced neurophysiological vulnerability, which could be involved in the pathophysiology of schizophrenia and related primary psychotic disorders. Then, we focus on adolescence as a "window of opportunity" for early pharmacological treatment, as novel risk reduction strategy for neurodevelopmental disorders. Thus, we review current preclinical and clinical evidence regarding the efficacy of CBD in terms of positive, negative and cognitive symptoms treatment, safety profile, and molecular targets.
Návaznosti
MUNI/A/1249/2020, interní kód MU |
| ||
3SGA5789, interní kód MU |
|